The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

被引:429
作者
Abboud, Camille [1 ]
Berman, Ellin [1 ]
Cohen, Adam [1 ]
Cortes, Jorge [1 ]
DeAngelo, Daniel [1 ]
Deininger, Michael [1 ]
Devine, Steven [1 ]
Druker, Brian [1 ]
Fathi, Amir [1 ]
Jabbour, Elias [1 ]
Jagasia, Madan [1 ]
Kantarjian, Hagop [1 ]
Khoury, Jean [1 ]
Laneuville, Pierre [1 ]
Larson, Richard [1 ]
Lipton, Jeffrey [1 ]
Moore, Joseph O. [1 ]
Mughal, Tariq [1 ]
O'Brien, Susan [1 ]
Pinilla-Ibarz, Javier [1 ]
Quintas-Cardama, Alfonso [1 ]
Radich, Jerald [1 ]
Reddy, Vishnu [1 ]
Schiffer, Charles [1 ]
Shah, Neil [1 ]
Shami, Paul [1 ]
Silver, Richard T. [1 ]
Snyder, David [1 ]
Stone, Richard [1 ]
Talpaz, Moshe [1 ]
Tefferi, Ayalew [1 ]
Van Etten, Richard A. [1 ]
Wetzler, Meir [1 ]
Abruzzese, Elisabetta [1 ]
Apperley, Jane [1 ]
Breccia, Massimo [1 ]
Byrne, Jenny [1 ]
Cervantes, Francisco [1 ]
Chelysheva, Ekaterina [1 ]
Clark, R. E. [1 ]
de Lavallade, Hugues [1 ]
Dyagil, Iryna [1 ]
Gambacorti-Passerini, Carlo [1 ]
Goldman, John [1 ]
Haznedaroglu, Ibrahim [1 ]
Hjorth-Hansen, Henrik [1 ]
Holyoake, Tessa [1 ]
Huntly, Brian [1 ]
le Coutre, Philipp [1 ]
Lomaia, Elza [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Leukemia Dept, Houston, TX 77030 USA
关键词
COST-EFFECTIVENESS; QUESTION; THERAPY; WORTH; ERA;
D O I
10.1182/blood-2013-03-490003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
引用
收藏
页码:4439 / 4442
页数:4
相关论文
共 25 条
[1]  
[Anonymous], NEW YORK TIMES 0727
[2]  
[Anonymous], RED BOOK ONLINE DATA
[3]  
[Anonymous], 2011, The Economist
[4]   Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008 [J].
Bjorkholm, Magnus ;
Ohm, Lotta ;
Eloranta, Sandra ;
Derolf, Asa ;
Hultcrantz, Malin ;
Sjoberg, Jan ;
Andersson, Therese ;
Hoglund, Martin ;
Richter, Johan ;
Landgren, Ola ;
Kristinsson, Sigurdur Y. ;
Dickman, Paul W. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) :2514-2520
[5]  
*BUND GES, ACT REF MARK MED PRO
[6]  
Centers for Medicare and Medicaid Services, NAT HLTH EXP PROJ 20
[7]   Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009 [J].
Chen, Yiming ;
Wang, Haijun ;
Kantarjian, Hagop ;
Cortes, Jorge .
LEUKEMIA & LYMPHOMA, 2013, 54 (07) :1411-1417
[8]  
*FED TRAD COMM, AUTH GEN DRUGS SHORT
[9]   How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question [J].
Fojo, Tito ;
Grady, Christine .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (15) :1044-1048
[10]   Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib [J].
Gambacorti-Passerini, Carlo ;
Antolini, Laura ;
Mahon, Francois-Xavier ;
Guilhot, Francois ;
Deininger, Michael ;
Fava, Carmen ;
Nagler, Arnon ;
Della Casa, Chiara Maria ;
Morra, Enrica ;
Abruzzese, Elisabetta ;
D'Emilio, Anna ;
Stagno, Fabio ;
le Coutre, Philipp ;
Hurtado-Monroy, Rafael ;
Santini, Valeria ;
Martino, Bruno ;
Pane, Fabrizio ;
Piccin, Andrea ;
Giraldo, Pilar ;
Assouline, Sarit ;
Durosinmi, Muheez A. ;
Leeksma, Onno ;
Pogliani, Enrico Maria ;
Puttini, Miriam ;
Jang, Eunjung ;
Reiffers, Josy ;
Valsecchi, Maria Grazia ;
Kim, Dong-Wook .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (07) :553-561